# Bayesian Two-Stage Biomarker-Based Adaptive Design for Targeted Therapy Development

- 323 Downloads
- 3 Citations

## Abstract

We propose a Bayesian two-stage biomarker-based adaptive randomization (AR) design for the development of targeted agents. The design has three main goals: (1) to test the treatment efficacy, (2) to identify prognostic and predictive markers for the targeted agents, and (3) to provide better treatment for patients enrolled in the trial. To treat patients better, both stages are guided by the Bayesian AR based on the individual patient’s biomarker profiles. The AR in the first stage is based on a known marker. A Go/No-Go decision can be made in the first stage by testing the overall treatment effects. If a Go decision is made at the end of the first stage, a two-step Bayesian lasso strategy will be implemented to select additional prognostic or predictive biomarkers to refine the AR in the second stage. We use simulations to demonstrate the good operating characteristics of the design, including the control of per-comparison type I and type II errors, high probability in selecting important markers, and treating more patients with more effective treatments. Bayesian adaptive designs allow for continuous learning. The designs are particularly suitable for the development of multiple targeted agents in the quest of personalized medicine. By estimating treatment effects and identifying relevant biomarkers, the information acquired from the interim data can be used to guide the choice of treatment for each individual patient enrolled in the trial in real time to achieve a better outcome. The design is being implemented in the BATTLE-2 trial in lung cancer at the MD Anderson Cancer Center.

## Keywords

Adaptive design Outcome-adaptive randomization Bayesian Lasso Predictive and prognostic biomarkers Personalized medicine Targeted therapy Variable selection## Notes

### Acknowledgments

The authors thank Ms. LeeAnn Chastain for editorial assistance. The work was supported in part by grants CA016672 and CA155196 from the National Cancer Institute. The clinical trial was supported in part by Merck Research Laboratories and Bayer HealthCare. We also would like to thank two anonymous reviewers, the associate editor, and the editor for their thorough review and constructive critiques. Our manuscript has been improved by providing answers in addressing these critics.

### Conflict of interest

The authors did not have any conflict of interest related to this work to disclose.

## Supplementary material

## References

- 1.DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22(2):151–185CrossRefGoogle Scholar
- 2.Herper M (2012) The truly staggering cost of inventing new drugs. Forbes Website. http://www.forbes.com/sites/matthewherper/2012/02/10/the-truly-staggering-cost-of-inventing-new-drugs/
- 3.CSDD Outlook (2009) Backgrounder: a methodology for counting cost for pharmaceutical R&D. Tufts Center for the study of Drug Development, BostonGoogle Scholar
- 4.Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711–716CrossRefGoogle Scholar
- 5.Spear BB, Heath-Chiozzi M, Huff J (2001) Clinical application of pharmacogenetics. Trends Mol Med 7:201–204CrossRefGoogle Scholar
- 6.Simon R (2010) Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology. Pers Med 7(1):33–47CrossRefGoogle Scholar
- 7.Mandrekar SJ, Sargent DJ (2009) Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol 27(24):4027–4034CrossRefGoogle Scholar
- 8.Mandrekar SJ, Sargent DJ (2001) Design of clinical trials for biomarker research in oncology. Clin Invest 1(12):1629–1636Google Scholar
- 9.Wang SJ (2007) Biomarker as a classifier in pharmacogenomics clinical trials: a tribute to 30th anniversary of PSI. Pharm Stat 6(4):283–296CrossRefGoogle Scholar
- 10.Scher HI, Nasso SF, Rubin EH, Simon R (2011) Adaptive clinical trial designs for simultaneous testing of matched diagnostics and therapeutics. Clin Cancer Res 17(21):6634–6640CrossRefGoogle Scholar
- 11.Goozner M (2012) Drug approvals 2011: focus on companion diagnostics. J Natl Cancer Inst 104(2):84–86CrossRefGoogle Scholar
- 12.Poste G, Carbone DP, Parkinson DR, Verweij J, Hewitt SM, Jessup JM (2012) Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development. Clin Cancer Res 18(6):1515–1523CrossRefGoogle Scholar
- 13.Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674CrossRefGoogle Scholar
- 14.Reck M, Gatzemeier U (2004) Chemotherapy in stage-IV NSCLC. Lung Cancer 45:s217–222CrossRefGoogle Scholar
- 15.Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH for the Eastern Cooperative Oncology Group (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98CrossRefGoogle Scholar
- 16.Silvestri G, Rivera M (2005) Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists. Chest 183:29–42Google Scholar
- 17.McClellan M, Benner J, Schilsky R et al (2011) An accelerated pathway for targeted cancer therapies. Nat Rev Drug Discov 10:79–80CrossRefGoogle Scholar
- 18.Chabner BA (2011) Early accelerated approval for highly targeted cancer drugs. N Engl J Med 364(12):1087–1089CrossRefGoogle Scholar
- 19.Bates SE, Amiri-Kordestani L, Giaccone G (2012) Drug development: portals of discovery. Clin Cancer Res 18(1):23–32CrossRefGoogle Scholar
- 20.Sharma MR, Schilsky RL (2012) Role of randomized phase III trials in an era of effective targeted therapies. Nat Rev Clin Oncol 9(4):208–214CrossRefGoogle Scholar
- 21.Rubin EH, Gilliland DG (2012) Drug development and clinical trials–the path to an approved cancer drug. Nat Rev Clin Oncol 9(4):215–222CrossRefGoogle Scholar
- 22.Zhou X, Liu SY, Kim ES, Herbst RS, Lee JJ (2008) Bayesian adaptive design for targeted therapy development in lung cancer–a step toward personalized medicine. Clin Trials 5:181–193CrossRefGoogle Scholar
- 23.Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK (2011) The BATTLE trial: Personalizing therapy for lung cancer. Cancer Discov 1(1):44–53CrossRefGoogle Scholar
- 24.Berry DA (2005) Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis. Clin Trials 2:295–300; discussion 301–304, 364–378Google Scholar
- 25.Berry DA (2006) A guide to drug discovery: Bayesian clinical trials. Nat Rev Drug Discov 5:27–36CrossRefGoogle Scholar
- 26.Berry DA (2011) Adaptive clinical trials in oncology. Nat Rev Clin Oncol 9(4):199–207CrossRefGoogle Scholar
- 27.Hu F, Rosenberger WF (2003) Optimality, variability, power: evaluating response-adaptive randomization procedures for treatment comparisons. J Am Stat Assoc 98:671–678MathSciNetCrossRefzbMATHGoogle Scholar
- 28.Hu F, Rosenberger WF (2006) The theory of response-adaptive randomization in clinical trials. Wiley, HobokenCrossRefzbMATHGoogle Scholar
- 29.Thall PF (2002) Ethical issues in oncology biostatistics. Stat Methods Med Res 11:429–448CrossRefzbMATHGoogle Scholar
- 30.Berry DA (2004) Bayesian statistics and the efficiency and ethics of clinical trials. Stat Sci 19:175–187Google Scholar
- 31.Korn EL, Freidlin B (2010) Outcome-adaptive randomization: is it useful? J Clin Oncol 21:100–120Google Scholar
- 32.Berry DA (2010) Adaptive clinical trials: the promise and the caution. J Clin Oncol 21:606–609Google Scholar
- 33.Lee JJ, Chen N, Yin G (2012) Worth adapting? Revisiting the usefulness of outcome-adaptive randomization. Clin Cancer Res 18(17):4498–4507CrossRefGoogle Scholar
- 34.Barker AD et al (2009) I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharm Ther 86:97–100CrossRefGoogle Scholar
- 35.Berry SM, Carlin BP, Lee JJ, Müller P (2010) Bayesian adaptive methods for clinical trials. Chapman & Hall, Boca RatonCrossRefzbMATHGoogle Scholar
- 36.Lee JJ, Gu X, Liu S (2010) Bayesian adaptive randomization designs for targeted agent development. Clin Trials 7(5):584–596CrossRefGoogle Scholar
- 37.Eickhoff JC, Kim K, Beach J, Kolesar JM, Gee JR (2010) A Bayesian adaptive design with biomarkers for targeted therapies. Clin Trials 7:546–556CrossRefGoogle Scholar
- 38.Lara PN, Natale R, Crowley J et al (2009) Phase III trial of irinotecan/cisplatin Compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 27:2530–2535CrossRefGoogle Scholar
- 39.Park T, Casella G (2008) The Bayesian lasso. J Am Stat Assoc 103(482):681–686MathSciNetCrossRefzbMATHGoogle Scholar
- 40.Zou H (2006) The adaptive lasso and its oracle properties. J Am Stat Assoc 101(476):1418–1429MathSciNetCrossRefzbMATHGoogle Scholar
- 41.Kyung M, Gill J, Ghosh M (2010) Penalized regression, standard errors, and Bayesian lassos. Bayesian Anal 5:369–412MathSciNetCrossRefzbMATHGoogle Scholar
- 42.Meier L, van de Geer S, Buhlmann P (2008) The group lasso for logistic regression. J R Stat Soc B 70:53–71MathSciNetCrossRefzbMATHGoogle Scholar
- 43.Chipman H (1996) Bayesian variable selection with related predictors. Can J Stat 24:17–36MathSciNetCrossRefzbMATHGoogle Scholar
- 44.McCullagh P, Nelder J (1989) Generalized linear models. Chapman and Hall, Boca RatonCrossRefzbMATHGoogle Scholar
- 45.Barbieri MM, Berger J (2004) Optimal predictive model selection. Ann Stat 32(3):870–897MathSciNetCrossRefzbMATHGoogle Scholar
- 46.Brannath W, Zuber E, Branson M, Bretz F, Gallo P, Posch M, Racine-Poon A (2009) Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology. Stat Med 28(10):1445–1463MathSciNetCrossRefGoogle Scholar
- 47.Biswas S, Liu DD, Lee JJ, Berry DA (2009) Bayesian clinical trials at the University of Texas MD Anderson Cancer Center. Clin Trials 6(3):205–216CrossRefGoogle Scholar
- 48.Lee JJ, Chu CT (2012) Bayesian clinical trials in action. Stat Med 31(25):2955–2972MathSciNetCrossRefGoogle Scholar
- 49.Wang S-J, Li M-C (2013) Impacts of predictive genomic classifier performance on subpopulation-specific treatment effects assessment. Stat Biosci. doi: 10.1007/s12561-013-9092-y